$VCYT

McGuire Annie sold $69K of VCYT

McGuire Annie (EVP, General Counsel) sold 1,400 shares of VERACYTE, INC. (VCYT) at $49.31 on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McGuire Annie
Published Jun 5, 2026, 1:38 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VCYT
Neutral
medium confidence
Mentioned
$VCYT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCYTNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not introduce new company fundamentals or catalysts.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a major repricing by itself.

03

What to watch

The sale size ($69k) is small relative to typical institutional float; without additional insider activity context, the signal-to-noise is low.

Relevance 6/10Novelty 3/10Timing: Filed June 4 after-hours; reflects sale executed on June 4.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by an EVP/General Counsel under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$VCYTNeutralMedium confidence
Context

Veracyte disclosed an officer (EVP, General Counsel) open-market sale of 1,400 shares on a Rule 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this single Form 4; any impact is likely limited to short-term sentiment.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory/drug data) and explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive value.

Market effects

Minimal; this is company-specific insider transaction with no stated operational or clinical linkage.

None.

None.

Counterpoint

Because it’s an officer sale (not a passive fund), some traders may still treat it as a mild negative sentiment input despite the 10b5-1 framing.

Key entities

  • Veracyte, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • McGuire Annie

    EVP, General Counsel who sold 1,400 shares at $49.3061 on June 4 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VCYTHigh

VERACYTE, INC. (VCYT): Results of Operations and Financial Condition

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS